ASCO: Novartis touts Kisqali adjuvant breast cancer data
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
Embracing AI Technology Will Be Key to the Future of UK Life...
ChatGPT’s explosive rise and Microsoft’s consequent investment stoked the flames under a life sciences industry that was already set to blossom.
How can pharma start-ups build themselves a positive future?
The global boom in start-up valuations has abruptly stopped.
Cosentyx nod ends 10-year drought in new biologics for HS
Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i
Mark Cuban will offer low-cost Humira thanks to Coherus deal
Billionaire and celebrity entrepreneur Mark Cuban has revealed his latest move to tackle the cost of medicines in the US, agreeing a deal to make a low-cost biosimilar ver
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Welcome to the 5th TIL Therapies Summit!
The first commercial TIL therapy is brewing at Iovance, along with various clinical readouts which are set to come to fruition in 2023, along with the 5th TIL Therapies Summit whic
2nd Process Development for Cell Therapies
View the program here
5th Exosome Based Therapeutic Development Summit
The 5th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translatio
8th CAR-TCR Summit
The 8th CAR-TCR Summit is returning to Boston as the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug develope
6th Targeted Protein Degradation Summit
Ensure your whole team stays connected and miles ahead of the curve with unmatched industry insights across early discovery, through the clinic and towards approval.